Pulmatrix Inc. Stock
€1.81
Your prediction
Pulmatrix Inc. Stock
Pros and Cons of Pulmatrix Inc. in the next few years
Pros
Cons
Performance of Pulmatrix Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pulmatrix Inc. | -2.690% | 12.422% | 2.841% | -7.841% | 10.501% | -85.925% | -87.951% |
| Evolus Inc | -3.360% | 5.109% | 20.000% | 68.421% | 59.116% | 114.925% | - |
| Ardelyx Inc. | 2.780% | -1.625% | 0.453% | 36.215% | -7.855% | 371.327% | 20.280% |
| Coherus Bioscien. | 3.430% | -20.402% | -16.557% | -77.568% | -68.750% | -93.667% | -95.188% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financial health of Pulmatrix, symbolized as PULM in the Biotechnology & Medical Research sector, presents a mixed picture. While some aspects indicate growth potential, others reveal significant challenges that the company must address. A closer examination of Pulmatrix’s financial statements uncovers several strengths and weaknesses that can influence future performance.
Starting off with the positives, Pulmatrix has shown a notable quarterly revenue growth year-over-year of 2.926%. This is an encouraging sign in a competitive industry where innovation and expansion are crucial for survival. Additional strength lies in the company’s gross profit of $6,071,000, which indicates that the business is generating revenue that covers its production costs. Moreover, with a book value of $5.207, there’s a considerable asset foundation backing the company.
However, juxtaposing these positives are substantial concerns. The negative EBITDA of -$9,247,000 highlights ongoing operational inefficiencies and a serious monetary outflow that raises red flags about the sustainability of current practices. The persistently negative profit margin of -0.7573 and a return on assets of -0.177 suggest that the company is not effectively translating revenues into profits, leading to potential cash flow issues moving forward. Even more troubling is the return on equity (ROE) of -0.3845, revealing that shareholder equity is eroding rather than growing.
Comments
